ANTI-TNF COMPOUNDS
First Claim
Patent Images
1. A compound comprising the structure depicted in FIG. 7 or salts thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
TNFα antisense oligonucleotides are provided herein. Methods of treating TNFα diseases or Initial Screen of Phosphodiester disorders using the TNFα antisense oligonucleotides and related products are provided.
8 Citations
69 Claims
-
1. A compound comprising the structure depicted in
FIG. 7 or salts thereof.
-
13. An oligonucleotide comprising mUmGmGmGmAmGT*A*G*A*T*G*mAmGmGmUmAmC (SEQ ID NO. 16), wherein the oligonucleotide is 18 nucleotides in length, wherein m is a 2′
- O methyl, and wherein * is a phosphorothioate modification.
- View Dependent Claims (14, 15, 16, 17, 18, 19, 20, 21, 22, 23)
-
24. An oligonucleotide comprising 5′
- TGGGAGTAGATGAGGTAC 3′
(SEQ ID NO.
4), wherein the oligonucleotide is 18-19 nucleotides in length, wherein 4-6 nucleotides at the 5′
end and 4-6 nucleotides at the 3′
end of the oligonucleotide include a 2′
O methyl, and wherein 4-10 nucleotides have a phosphorothioate modification. - View Dependent Claims (25, 26)
- TGGGAGTAGATGAGGTAC 3′
-
27-34. -34. (canceled)
-
35. A stable self-assembling nanostructure, comprising
an antisense oligonucleotide of 18-19 nucleotides in length comprising TGGGAGTAGATGAGGTAC (SEQ ID NO. 4), wherein the antisense oligonucleotide is associated with a core.
-
36-53. -53. (canceled)
-
57-63. -63. (canceled)
-
65. (canceled)
-
66. (canceled)
-
68. A stable self-assembling nanostructure, comprising an antisense oligonucleotide of 18-19 nucleotides in length comprising TGGGAGTAGATGAGGTAC (SEQ ID NO. 4), wherein a hydrophobic group at the 3′
- or 5′
terminus self-associates to form the core of the nanostructure in water or other suitable solvents.
- or 5′
-
69-72. -72. (canceled)
Specification